European Journal of Cancer and Clinical Oncology最新文献_第9页

The out-patient use of recombinant human interleukin-2 and interferon alfa-2b in advanced malignancies 重组人白细胞介素-2和干扰素-2b在晚期恶性肿瘤中的门诊应用

European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 DOI: 10.1016/0277-5379(91)90586-3

Jens Atzpodien, Hartmut Kirchner

{"title":"The out-patient use of recombinant human interleukin-2 and interferon alfa-2b in advanced malignancies","authors":"Jens Atzpodien, Hartmut Kirchner","doi":"10.1016/0277-5379(91)90586-3","DOIUrl":"10.1016/0277-5379(91)90586-3","url":null,"abstract":"<div><p>We studied the safety, tolerance, and clinical effects of the combined administration of subcutaneous recombinant human interleukin-2 and interferon alfa-2b in 54 patients with advanced cancer, for whom no effective standard therapy was available. Treatment courses consisted of a 2-day interleukin-2 pulse (14.4–18 million units (MU) m<sup>2</sup>/day), followed by 3.6 up to 4.8 MU/m<sup>2</sup>/day, 5 days per week, over 6 consecutive weeks and interferon alfa-2b at 3 up to 6 MU/m<sup>2</sup>, administered two-three times weekly for 6 weeks. Overall, patients received more than 90% of the projected dose of interleukin-2 and interferon alfa-2b, respectively. Of 54 evaluable patients (32 renal cell cancer, 12 melanoma, eight colorectal cancer, one B-cell lymphoma, one Hodgkin's disease), four complete responses occurred in patients with renal cell carcinoma, and a greater than 50% reduction in tumour size (partial response) in six renal cell carcinoma patients and one melanoma patient. Moreover, 21 patients (13 renal carcinoma) had stable disease. The median duration of response was 19 months (range 16–22 months) in complete responders. Clinical responses were associated with a mean peripheral blood eosinophil count of more than 1,000/μL (<em>P</em> < 0.05 versus non-responders). Systemic toxicities included fever, chills, nausea, anorexia, and hypotension limited to WHO grades I and II in more than 80% of patients treated. No treatment-related deaths occurred. This combination of subcutaneously administered recombinant interleukin-2 and interferon alfa-2b has significantly diminished the side effects normally observed with high-dose intravenous recombinant interleukin-2, which requires admission to hospital. It has been shown to induce objective tumour regression in out-patients with progressive metastatic renal cell carcinoma and malignant melanoma.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90586-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12961460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 25

Phase II study of weekly 5-fluorouracil, cisplatin and vinblastine in advanced non-small cell lung cancer 5-氟尿嘧啶、顺铂和长春碱治疗晚期非小细胞肺癌的II期临床研究

European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 DOI: 10.1016/0277-5379(91)90420-I

Peter J. O'Dwyer, Corey J. Langer, Judy Walczak, Michael H. Levy, Kristin Padavic-Shaller, Gary R. Hudes, Sam Litwin, Robert L. Comis

{"title":"Phase II study of weekly 5-fluorouracil, cisplatin and vinblastine in advanced non-small cell lung cancer","authors":"Peter J. O'Dwyer, Corey J. Langer, Judy Walczak, Michael H. Levy, Kristin Padavic-Shaller, Gary R. Hudes, Sam Litwin, Robert L. Comis","doi":"10.1016/0277-5379(91)90420-I","DOIUrl":"10.1016/0277-5379(91)90420-I","url":null,"abstract":"<div><p>The scheduling of chemotherapeutic agents may be important in optimising their antitumour actions. This has been explored in non-Hodgkin lymphoma, osteogenic sarcoma and bladder cancer with improved results using intensive, weekly dosing schemas. We began a phase II study of cisplatin, 5-fluorouracil and vinblastine in non-small cell lung cancer (NSCLC) on a weekly schedule. 38 patients with advanced or metastatic NSCLC were entered; 32 are evaluable for response. 11 patients were treated with 5-fluorouracil 1.5 g/m<sup>2</sup> and vinblastine 4 mg/m<sup>2</sup> by 24-h continuous infusion, and cisplatin 30 mg/m<sup>2</sup> over 30 min, 6–8 h after the start of the infusion. Because of prohibitive myelotoxicity, the next 27 patients received 5-fluorouracil 1.2 g/m<sup>2</sup> and vinblastine 3 mg/m<sup>2</sup>. None had had prior chemotherapy while 6 had had previous radiation therapy. Myelosuppression was the predominant toxic effect. Other side-effects included neuropathy, diarrhoea, mucositis, nausea and vomiting. 32 patients are evaluable for response: there have been 14 partial remissions (44%). Responses have occurred chiefly in lung and lymph nodes. The median survival on this study is 7 months, and responders did not live longer than non-responders. While this regimen is well tolerated by the majority of patients and has a response rate comparable to other active regimens identified in single institution studies, survival does not appear to be enhanced. We conclude that the schedule manipulation described here does not enhance the therapeutic index of these drugs in NSCLC.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90420-I","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12829431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Recombinant interleukin-2 in metastatic renal cell carcinoma—A European multicentre phase II study 重组白介素-2在转移性肾细胞癌中的作用——一项欧洲多中心II期研究

European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 DOI: 10.1016/0277-5379(91)90419-E

H. von der Maase , P. Geertsen , N. Thatcher , C. Jasmin , A. Mercatello , S.D. Fosså , M. Symann , G. Stoter , G. Nagel , L. Israel , R. Oskam , P. Palmer , C.R. Franks

{"title":"Recombinant interleukin-2 in metastatic renal cell carcinoma—A European multicentre phase II study","authors":"H. von der Maase , P. Geertsen , N. Thatcher , C. Jasmin , A. Mercatello , S.D. Fosså , M. Symann , G. Stoter , G. Nagel , L. Israel , R. Oskam , P. Palmer , C.R. Franks","doi":"10.1016/0277-5379(91)90419-E","DOIUrl":"10.1016/0277-5379(91)90419-E","url":null,"abstract":"<div><p>This multinational, multicentre study represents the introduction of recombinant interleukin-2 (rIL-2) in Europe. From December 1987 to June 1989, 57 eligible patients with metastatic renal cell cancer were treated with rIL-2 administered as continuous intravenous infusion. 8 out of 51 evaluable patients responded (16%), 2 complete remission (CR) and 6 partial remission (PR). 10 patients had no change (20%). The response duration for CR was 209 and 394+ days. The median response duration for PR was 371 (range 140–506+) days. Dose-limiting grade 3–4 toxicities were hypotension in 52% of the patients, arrhythmia (4%), dyspnoea (8%), creatinine rise (4%), peripheral neurotoxicity (10%) and central neurotoxicity (10%). Toxicities most often recovered solely on interrupted therapy. 2 patients died due to catheter-related septicaemia and one patient died of rIL-2 induced renal failure. The study confirmed the antitumour efficacy of rIL-2 in renal cell cancer. Toxicities were numerous, but manageable by close observation in a normal oncology ward without routine use of an intensive care unit.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90419-E","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12943917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 47

Maintenance treatment of multiple myeloma with alpha interferon versus an alternating schedule of alpha interferon and chemotherapy 干扰素对多发性骨髓瘤的维持治疗与干扰素和化疗交替计划

European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 DOI: 10.1016/0277-5379(91)90573-V

Alice Maniatis, Greek Myeloma Study Group (GMSG)

引用次数: 0

Hairy cell leukaemia: The role of alpha interferon 毛细胞白血病:干扰素的作用

European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 DOI: 10.1016/0277-5379(91)90575-X

Leonidas C. Platanias , Mark J. Ratain

引用次数: 7

Alpha interferon: The potential drug of adjuvant therapy: Past achievements and future challenges 干扰素:辅助治疗的潜在药物:过去的成就和未来的挑战

European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 DOI: 10.1016/0277-5379(91)90555-R

Eric M. Bonnem

{"title":"Alpha interferon: The potential drug of adjuvant therapy: Past achievements and future challenges","authors":"Eric M. Bonnem","doi":"10.1016/0277-5379(91)90555-R","DOIUrl":"10.1016/0277-5379(91)90555-R","url":null,"abstract":"<div><p>This paper aims to summarize current experience with alpha interferon and provide direction for future study. There are four areas in which alpha interferon has proven or potential activity: antiviral, premalignant, adjuvant and advanced disease settings. The three main viral diseases in which interferon alfa-2b has been shown to have activity are chronic viral hepatitis, acquired immunodeficiency syndrome, and human papilloma virus infections. <em>In vitro</em> studies suggest that alpha interferon may inhibit transformation of some premalignant conditions into malignant disease; e.g., vaginal intraepithelial neoplasia. In the adjuvant setting, it is possible that a biological response modifier, such as alpha interferon, may have a role in helping the immune system to destroy residual tumour cells following tumour bulk reduction with radiation or chemotherapy. A higher response rate has been seen in patients with small tumour bulk compared to those with large tumour bulk (e.g., malignant melanoma, ovarian carcinoma), and in patients with early, rather than late, disease (e.g., chronic myelogenous leukaemia, hairy cell leukaemia, multiple myeloma, non-Hodgkin's lymphoma). This may be due to efficacy in a small tumour bulk setting or due to an immunoadjuvant role. In advanced disease, the question is how best to exploit the possible synergistic effects between alpha interferon and other therapeutic modalities. The optimum dose, schedule and patient populations for combined treatment have yet to be determined. The major objective of this paper is to determine how best to capitalize upon the current state of knowledge to build for future trials of alpha interferon, and to determine whether the existing data suggest an adjuvant role for interferon after initial tumour regression.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90555-R","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12962478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

Alpha interferon in chronic lymphocytic leukaemia 干扰素在慢性淋巴细胞白血病中的作用

European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 DOI: 10.1016/0277-5379(91)90580-7

Emilio Montserrat , Neus Villamor , Alvaro Urbano-Ispizua , Josep-Maria Ribera , Ciril Rozman

{"title":"Alpha interferon in chronic lymphocytic leukaemia","authors":"Emilio Montserrat , Neus Villamor , Alvaro Urbano-Ispizua , Josep-Maria Ribera , Ciril Rozman","doi":"10.1016/0277-5379(91)90580-7","DOIUrl":"10.1016/0277-5379(91)90580-7","url":null,"abstract":"<div><p>The role of alpha interferon in patients with chronic lymphocytic leukaemia (CLL) has yet to be well established. In studies carried out to date, a significantly higher response rate has been observed in previously untreated patients compared to those who have received prior chemotherapy. Patients with early-stage CLL also respond better than patients with advanced disease. Responses to alpha interferon are transient and complete responses are rare. It is not yet known whether alpha interferon can induce clonal remission, and response is usually measured in terms of the reduction in peripheral blood lymphocyte levels. In one study, a normalization of immunoglobulin levels was observed, and in another there was an increase in the absolute number of granulocytes. Further studies are needed to investigate the role of combined therapy with alpha interferon and cytotoxic agents or other cytokines, and to assess the ability of alpha interferon to prolong response duration after remission induction with chemotherapy. Toxicity is tolerable when alpha interferon is given in a low dose (e.g., 2 million units (MU)/m<sup>2</sup> three times a week) and low doses have been shown to be as effective as high doses in CLL patients.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90580-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13000431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 16

Rational design of sequence-specific oncogene inhibitors based on antisense and antigene oligonucleotides 基于反义和抗原寡核苷酸的序列特异性癌基因抑制剂的合理设计

European Journal of Cancer and Clinical Oncology Pub Date : 1991-11-01 DOI: 10.1016/0277-5379(91)90033-A

Claude Hélène

引用次数: 114

Metastatic carcinoid and islet cell tumours of the pancreas: A phase II trial of the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin and cisplatin 胰腺转移性类癌和胰岛细胞肿瘤:5-氟尿嘧啶、阿霉素和顺铂联合化疗疗效的II期试验

European Journal of Cancer and Clinical Oncology Pub Date : 1991-11-01 DOI: 10.1016/0277-5379(91)90014-5

Ph. Rougier, J. Oliveira, M. Ducreux, C. Theodore, J. Kac, J.P. Droz

引用次数: 48

Factors influencing the response of MCF-7 cells to an agonist of luteinising hormone-releasing hormone 影响MCF-7细胞对黄体生成素释放激素激动剂反应的因素

European Journal of Cancer and Clinical Oncology Pub Date : 1991-11-01 DOI: 10.1016/0277-5379(91)90031-8

William N. Scott, Peter Mullen, William R. Miller

引用次数: 8